Osi Pharmaceuticals (NASDAQ:OSIP)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Osi Pharmaceuticals Charts. Click Here for more Osi Pharmaceuticals Charts.](/p.php?pid=staticchart&s=N%5EOSIP&p=8&t=15)
OSI Pharmaceuticals, Inc. (NASDAQ: OSIP) announced today that it will
host a live webcast of its R&D Analyst Day on Thursday, December 4, 2008
at 12:30 p.m. Eastern Time. The webcast will be hosted by Colin Goddard,
Ph.D., Chief Executive Officer, and members of OSI’s management team.
The Company will discuss the status of its oncology and diabetes/obesity
research and development programs, including its Tarceva®
(erlotinib) program. The webcast is expected to last approximately three
hours.
To access the webcast live via the Internet, please log onto www.osip.com
approximately 15 minutes before the start of the event to allow for any
software downloads that may be necessary. Following the webcast, an
archive will be available at the same address until approximately
December 31, 2008.
About OSI Pharmaceuticals
OSI Pharmaceuticals is committed to "shaping medicine and changing
lives" by discovering, developing and commercializing high-quality and
novel pharmaceutical products designed to extend life and/or improve the
quality of life for patients with cancer and diabetes/obesity. The
Company’s oncology programs are focused on developing molecular targeted
therapies designed to change the paradigm of cancer care. OSI’s
diabetes/obesity efforts are committed to the generation of novel,
targeted therapies for the treatment of type 2 diabetes and obesity.
OSI's flagship product, Tarceva® (erlotinib), is the first
drug discovered and developed by OSI to obtain FDA approval and the only
EGFR inhibitor to have demonstrated the ability to improve survival in
both non-small cell lung cancer and pancreatic cancer patients in
certain settings. OSI markets Tarceva through partnerships with
Genentech, Inc. in the United States and with Roche throughout the rest
of the world. For additional information about OSI, please visit .
This news release contains forward-looking statements. These
statements are subject to known and unknown risks and uncertainties that
may cause actual future experience and results to differ materially from
the statements made. Factors that might cause such a difference
include, among others, the completion of clinical trials, the FDA review
process and other governmental regulation, OSI's and its collaborators'
abilities to successfully develop and commercialize drug candidates,
competition from other pharmaceutical companies, the ability to
effectively market products, and other factors described in OSI
Pharmaceuticals' filings with the Securities and Exchange Commission.